Processa Letter Puts As-Converted Share Count at 309.3M vs 2.8M Trading
PCSA sits 78% above its 52-week low of $1.041 on light trading volume (0.3× avg).
Summary
Processa's stockholder letter recaps the Vidya deal and IND clearance but newly quantifies the capital structure: 2.8 million common shares trading against 306.5 million Series A preferred shares as-converted, pending a second special meeting vote. It also states the July financing netted about $183.3 million and funds operations into the second half of 2029.
Key Events · Corporate Governance and Compliance · PCSA
-
As-Converted Share Count Disclosed
The letter states 2.8 million common shares are currently outstanding versus 306.5 million Series A preferred shares as-converted, for approximately 309.3 million total common shares as-converted.
-
Conversion Needs a Second Vote
Conversion of the Series A non-voting preferred into common requires stockholder approval at a second special meeting; definitive proxy materials for that meeting are still forthcoming, separate from the October 22, 2026 reverse-split proxy.
-
Net Proceeds and Runway Stated
The July financing generated approximately $183.3 million in net proceeds and is expected to fund operations into the second half of 2029, covering the Phase 2 proof-of-concept plan in food allergy, CSU and relapsing MS.
-
Reverse Split Still Pending
A separate special meeting will vote on a reverse stock split to maintain Nasdaq listing compliance, per the definitive proxy filed October 22, 2026.
Analysis · PCSA · Life Sciences
The letter is mostly a recap of the July Vidya deal, the October proxy filings and the October 29 IND clearance. What is new is the capitalization math: only about 2.8 million common shares trade today, while roughly 306.5 million more sit in Series A preferred that converts to common if stockholders approve. That approval is the subject of a second special meeting whose definitive proxy has not yet been filed, so the overhang is real but not yet tradable. The letter also puts the July raise at about $183.3 million in net proceeds with runway into the second half of 2029, which is the first hard funding figure tied to the Phase 2 plan. Investors holding the 2.8 million trading shares face the prospect of their stake being diluted roughly 110-fold on an as-converted basis if conversion is approved.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCSA was trading at $1.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $1.04 to $9.30. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.